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Immune dysregulation, Polyendocrinopathy, Enteropathy X-linked (IPEX) syndrome is a unique example
of primary immunodeﬁciency characterized by autoimmune manifestations due to defective regulatory T
(Treg) cells, in the presence of FOXP3 mutations. However, autoimmune symptoms phenotypically
resembling IPEX often occur in the absence of detectable FOXP3 mutations. The cause of this “IPEX-like”
syndrome presently remains unclear.
To investigate whether a defect in Treg cells sustains the immunological dysregulation in IPEX-like
patients, we measured the amount of peripheral Treg cells within the CD3þ T cells by analysing deme-
thylation of the Treg cell-Speciﬁc-Demethylated-Region (TSDR) in the FOXP3 locus and demethylation of
the T cell-Speciﬁc-Demethylated-Region (TLSDR) in the CD3 locus, highly speciﬁc markers for stable Treg
cells and overall T cells, respectively.
TSDR demethylation analysis, alone or normalized for the total T cells, showed that the amount of
peripheral Treg cells in a cohort of IPEX-like patients was signiﬁcantly reduced, as compared to both
healthy subjects and unrelated disease controls. This reduction could not be displayed by ﬂow cytometric
analysis, showing highly variable percentages of FOXP3þ and CD25þFOXP3þ T cells. These data provide
evidence that a quantitative defect of Treg cells could be considered a common biological hallmark of
IPEX-like syndrome. Since Treg cell suppressive function was not impaired, we propose that this
reduction per se could sustain autoimmunity.
 2011 Elsevier Ltd.Open access under CC BY-NC-ND license.: þ39 2 26434668.
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Primary immunodeﬁciencies are usually due to effector T (Teff)
cell impairment and manifest with defective immune responses to
pathogens. However, autoimmunemanifestations are often present
or can even prevail over recurrent infections when the genetic
defect affects regulatory T (Treg) cells, which are the major players
F. Barzaghi et al. / Journal of Autoimmunity 38 (2012) 49e5850in maintaining peripheral tolerance [1]. This cell subset is impaired
in Immune dysregulation, Polyendocrinopathy, Enteropathy
X-linked (IPEX) syndrome, a disease caused by mutations in fork-
head box p3 (FOXP3) gene, the master switch for the function of
Treg cells [2]. Affected males show life threatening autoimmune
manifestations, including severe neonatal enteropathy and
eczematous dermatitis, frequently associated with type 1 diabetes
mellitus (T1DM) and elevated IgE serum levels [3e5].
Notably, in about one third of patients, with clinical symptoms
closely resembling IPEX syndrome, FOXP3 is not mutated. These
patients are here referred to as IPEX-like [6e10]. Most frequently,
the underlying genetic defect leading to IPEX-like syndrome, if
present, remains unknown, thus limiting both diagnosis and ther-
apeutic strategies. Phenotypic manifestations similar to those re-
ported for scurfy mice, the natural foxp3mutants, have been found
also in mice with genetic defects affecting different molecules
involved in Treg cells signalling and function, such as IL-2Ra, IL-2,
CTLA-4 and STAT5 [11e14]. In humans, a small number of
patients with causative mutations in CD25 [7,15] or STAT5b [16e19]
have been reported and most likely these genetic defects cannot
account for the majority of IPEX-like cases.
While in IPEX patients Treg cells, although present, are func-
tionally impaired [4,8,20,21], the contribution of an altered Treg cell
compartment in the pathogenesis of IPEX-like syndromes remains
elusive. Reduced proportion of peripheral FOXP3 expressing T cells,
as determined by ﬂow cytometric analysis, and their reduced
inhibitory activity have been recently reported in two IPEX-like
patients under immune suppressive treatment [8], whereas, in
another work describing a single IPEX-like patient, a low FOXP3þ
cell amount at ﬂow cytometric analysis but preserved suppressive
function was shown [9]. Indeed, peripheral Treg cell detection and
quantiﬁcation in humans has been so far limited by the fact that the
main markers for their identiﬁcation, CD25 and FOXP3, are also
expressed by activated Teff cells [2,22,23], which can be increased in
inﬂammatory conditions [22,24], typically occurring in autoim-
mune diseases. Also, the use of CD127 as additional marker to
discriminate Treg cells from activated Teff cells does not allow
precise deﬁnition of the Treg cell subset by phenotypic analysis,
since Teff cells down-regulate CD127 upon activation [24]. Recently,
a highly conserved CpG enriched element, located in the 50
untranslated region (50UTR) of FOXP3 has been identiﬁed as the Treg
cell-speciﬁc-demethylated-region (TSDR), since it is constantly
demethylated exclusively in Treg cells [25]. Demethylation of the
TSDR is associated with high and stable expression of FOXP3
[26e28] and quantiﬁcation of the cells carrying demethylated TSDR
allows to measure the peripheral proportion of bona ﬁde Treg cells
vs Teff cells, that maintain a fully methylated TSDR [25,29]. The
reliability of this method for the detection of Treg cells in peripheral
blood and tissues for clinical purposes has already been demon-
strated in cancer patients [29,30].
In this study we quantiﬁed Treg cells in the peripheral blood of
IPEX-like patients by analysing the demethylation status of the
TSDR. In parallel, we evaluated the amount of CD3þ T cells by an
approach analogous to the TSDR analysis using a speciﬁcally
demethylated area in the intergenic regions of the CD3d and CD3g
genes, a region we here refer to as “T-lymphocyte-speciﬁc-deme-
thylated-region” (TLSDR) [30]. Using these methods, we were able
to evaluate the relative proportion of peripheral Treg within the
total T cells in these patients. Our ﬁndings show a quantitative
defect in the Treg cell compartment, suggestive of decreased
peripheral tolerance in IPEX-like disease. The TSDR demethylation
assay showed good speciﬁcity and sensitivity, thus candidating this
method as a potential tool for quantiﬁcation of Treg cells in the
peripheral blood of patients with immune dysregulation, alterna-
tive or complementary to the ﬂow cytometric analysis.2. Material and methods
2.1. Patients
Twenty-eight IPEX-like patients (23 males and 5 females) with
clinical manifestations resembling IPEX in absence of FOXP3
mutations, were enrolled for this study (samples collected from
2006 to 2010). Clinical and laboratory parameters allowed exclu-
sion of other monogenic diseases, such as Wiskott Aldrich
syndrome, Omenn’s syndrome, Hyper IgE syndrome and autoim-
mune lymphoproliferative syndrome, which should be always
considered in the differential diagnosis. Patients presented at least
one of the main clinical features of IPEX syndrome, autoimmune
enteropathy and/or type 1 diabetes mellitus, associated with one
or more of the following: dermatitis, autoimmune thyroiditis,
autoimmune haemolytic anemia, autoimmune thrombocytopenia,
nephropathy, autoimmune hepatitis, alopecia, hyper IgE (with or
without eosinophilia). The age of the patients ranged from 2
months to 38 years (median 5 years). All patients were investi-
gated for the presence of mutations in FOXP3 and found to be
negative. In two patients, a homozygous point mutation of CD25
was found. The clinical details of 23 patients were available and
are summarized in Table 1. Molecular and clinical details of
subjects with IPEX syndrome, included as a control group in
Fig. 3C, are described elsewhere [4] (Pt 3, 9, 11, 12, 14). Twenty-
seven patients (non-lymphopenic, both male and female) with
well deﬁned autoimmune and autoinﬂammatory diseases,
different from IPEX-like syndrome, have been included as patho-
logic controls (type 1 diabetes mellitus, n ¼ 10; celiac disease,
n ¼ 9; Crohn’s disease, n ¼ 8). Forty healthy subjects (HS), aged
between 7 months and 32 years (median 9 years), were analysed
in parallel. The group of HS was equally distributed among males
(n ¼ 21) and females (n ¼ 19); since no difference was detected in
Treg cell percentage, even when normalized to CD3 (not shown),
males and females were pooled in a single control group.
Peripheral blood was obtained from patients and HS upon
informed consent in accordance with the ethical committee of San
Raffaele Scientiﬁc Institute approval (protocol TIGET02 and TIGET
PeriBlood).
2.2. TSDR and TLSDR demethylation analysis
Genomic DNA for TSDR analysis was isolated using the QIAamp
DNA micro kit (Qiagen) from peripheral blood. Bisulﬁte treatment
of genomic DNA, subsequent TSDR- and TLSDR-speciﬁc RT-PCR
and quantitative evaluation of methylated and unmethylated
FOXP3 and CD3 DNA were performed as previously described by
Wieczorek G. et al. and by Sehouli J. et al., respectively [29,30].
Bisulﬁte conversion was performed using Qiagen Epitect,
following the manufacturer’s instructions and the efﬁciency of
conversion was always over 99%, tested according to Lewin et al.
[31]. TSDR demethylation analysis evaluates the methylation
status of nucleated cells in the peripheral blood, discriminating
Treg (TSDR-demethylated) from all non-Treg (TSDR-methylated)
cells. Hence, Treg cell amount is expressed as percentage of total
nucleated cells of the peripheral blood. Based on TLSDR analysis
a patient is considered lymphopenic if CD3-expressing cell
percentage on the total nucleated peripheral blood cells is below
14.9% (i.e. the minimum value detected in the cohort of HS
included in the present study).
2.3. Flow cytometric analysis
Anti-CD4 and -CD25 mAbs (BD Pharmingen) were used for
surface staining. Intracellular staining for FOXP3 (clone 259D,
Table 1
Clinical ﬁndings in the cohort study of IPEX-like patients.
# Age Onset GI symptoms Endocrinopathy Skin Infections Other Therapy L
1a 5y 1m Enteropathy,
VA
Thyroiditis Psoriasiform
dermatitis,
Alopecia
universalis
Chronic CMV
infection
No FK506 Y
2 3y 7m 2y Enteropathy No No No Nephropathy,
Thrombosis
PD, AZA Y
3 2y 5m Enteropathy,
VA, Vomiting
No No Sepsis Hypothyroidism
(uncertain origin)
PN N
4 10y na Enteropathy No Erythrodermia No Nephrotic syndrome AZA N
5 2m 2m Enteropathy,
Vomiting
No No No Eosinophilia TPN N
6 18y 2y Enteropathy,
VA
T1DM Esfoliative
dermatitis,
Alopecia,
fragile nails
Sepsis Glomerulonephritis,
Thrombocytopenia,
AHA, A. hepatitis,
Vasculitis
Steroids, FK506 Y
7 4y 6m Enteropathy T1DM Eczema No No No Y
8 4m 2m Enteropathy No No No No IS Y
9 3m 2m Enteropathy Thyroiditis Eczema Sepsis Abnormal CNS seizures,
Abnormal EEG ﬁndings
Ig IV Y
10 3m 2m Enteropathy,
VA
No No No No MPD, CS N
11 16y 7y Intermittent
enteropathy
No Nodular
eritema
RRI Chronic nephritis Steroids, AZA Y
12 7y 4m Enteropathy No Bullous
pemphigoid
No AHA, A. hepatitis, arthritis Steroids, Rituximab,
MMF, Cx
Y
13 5y 5m Enteropathy,
Vomiting
T1DM Vitiligo No No Past steroids, TPN N
14 20y Neonatal Enteropathy No Mild eczema RRI A. hepatitis, Failure
to thrive
FK506 N
15 1y 9m 9m Enteropathy Thyroiditis Atopic dermatitis CMV colitis,
Otitis, pneumonia
No PD, AZA N
16 2m Neonatal Enteropathy No No No No MPD Y
17 10y 6y Ulcerative
colitis
T1DM Urticaria-like Recurrent otitis,
Tonsillitis
Hypogammaglobulinemia,
Partial IgAD
5-ASA N
18 2y 5m 1y No T1DM Eczema, Alopecia No Growth retardation,
Hyper IgE
No N
19 38y 19y Enteropathy T1DM,
thyroiditis
Psoriasis Recurrent
foruncolosis
IgAD, AAG, AT PD N
20 34y 10y Enteropathy No Vitiligo, Alopecia Recurrent
infections (upper
airways, sinusitis,
pneumonias,
meningitis)
Hypogammaglobulinemia,
AAG
Ig IV N
21 33y 17y Ulcerative
colitis
No Parapsoriasis No Ankylosing spondylitis,
A. colangytis,
interstitial pneumonia,
hyper IgE
PD N
22a 4m 20d Enteropathy T1DM,
Thyroiditis
Mild eczema CMV infection,
Pneumonia
AHA, lymphadenopathy,
CNS bleeding, Axial
hypotonia, Failure to thrive,
Hyper IgE, Hyper IgG, IgA
Ig IV N
23 1y 5m 6m Enteropathy,
VA, Gastric
and colonic
ulcers
No No No Hyper IgE, Eosinophilia,
Food allergy
MPD N
GI: gastrointestinal; VA: villous atrophy; T1DM: Type 1 diabetes mellitus; CMV: cytomegalovirus; RRI: recurrent respiratory infections; A: autoimmune; CNS: central nervous
system; AHA: autoimmune haemolytic anemia; IgAD: IgA deﬁciency; AAG: autoimmune atrophic gastritis; AT: autoimmune thrombocytopenia; FK506: tacrolimus; PD:
prednisone; AZA: azathioprine; PN: parenteral nutrition; TPN: total parenteral nutrition; IS: immunosuppressive drugs; IV: intravenous; MPD: methylprednisone; CS:
corticosteroid; MMF: mycophenolate mophetyl; Cx: cyclophosphamide; 5-ASA: mesalazine; L: lymphocytes count; na: not available; N: normal.
a Patient with CD25 mutation.
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tions. Samples were acquired on BD FACSCanto and analysed with
FCS Express Pro Software Version 3 (De Novo Software).
2.4. T cell puriﬁcation and suppression assays
PBMC were puriﬁed over Ficoll-hypaque gradients. Treg cells
were isolated either by FACS-sorting of CD4þCD25bright T cells
or magnetic bead sorting by negative selection of CD4þ T cells
followed by positive selection of CD25þ T cells and were over 90%pure (Miltenyi Biotec). To evaluate Treg cell suppressive activity,
PBMC, used as responders, were stained with CFSE (Molecular
Probes), following the manufacturer’s instructions, and activated in
the presence of Treg Inspector coated beads (Miltenyi Biotec).
Suppressor cells were added at a variable ratio and the percentage
of divided responders after six days of co-culture was calculated by
gating on CD4þ and/or CD8þ cells, as elsewhere described [32]. The
suppressive function of Patient #15 Treg cells was evaluated as
follows: allogeneic CD4þCD25 T cells selected by magnetic bead
sorting were used as responders, activated in the presence of
Fig. 2. Flow cytometric analysis of Treg cells in the peripheral blood of IPEX-like patients. FOXP3þ cells were detected by ﬂow cytometry in the peripheral blood of IPEX-like patients
(n ¼ 13) and HS (n ¼ 25). Percentage of FOXP3þ T cells in the (A) CD4þ and (B) CD4þCD25þ T cell gates are plotted in the graphs. Mean ﬂuorescence intensity of marker expression in
(C) CD4þFOXP3þ and (D) CD4þCD25þ T cells is also shown. Differences between groups were veriﬁed by means of ManneWhitney U-test.
Fig. 1. TSDR demethylation analysis in the peripheral blood of IPEX-like patients. (A) Comparison between median Treg percentages (measured by TSDR demethylation assay), in
the peripheral blood of HS (white bar, n ¼ 40) and IPEX-like patients (grey bar, n ¼ 28). Middle line indicates the median. The box represents 50% of all events and the whiskers
extend to 95%. Statistical analysis was performed with ManneWhitney U-test. (B) ROC curve describing the performance of TSDR assay in discriminating patients and HS. AUC value
reﬂecting the discrimination between groups is indicated. (C, D) Scatter plot and linear regression between the percentage of Treg cells and age in healthy paediatric controls
(n ¼ 27), and IPEX-like paediatric patients (n ¼ 22), all under 16 years.
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Fig. 3. Treg cell normalization to CD3þ T cell counts. (A) Robust regression plots of the % of Treg cells vs the % of CD3-expressing cells (as measured by TSDR and TLSDR assays) in the
peripheral blood of HS (left panel) and IPEX-like patients (right panel) are shown. Pearson correlation values were 0.617 (p < 0.001) for HS and 0.476 (p ¼ 0.010) for patients. (B) The
percentage of Treg cells normalized to TLSDR was plotted versus the CD3þ cell counts, as measured by TLSDR assay. Region (I) comprises lymphopenic patients, in whom the % of
CD3-expressing cells in whole blood was below 14.9%; region (II) identiﬁes patients with lymphocyte cell counts within normal ranges. (C) The box-plots show the % of Treg
normalized to CD3þ T cell amount (as measured by TSDR and TLSDR combined analysis) in HS (white bar) and non-lymphopenic IPEX-like (light grey) and control patients (dark
grey). Control pathologies include: IPEX syndrome (n ¼ 5), T1DM (n ¼ 10), Celiac (n ¼ 9) and Crohn (n ¼ 8) diseases. Middle lines represent the median. Statistical analysis was
performed with ManneWhitney U-test, p < 0.05 was considered signiﬁcant. (D) The ROC curve describes the performance of the combined TSDR/TLSDR assays in discriminating HS
and IPEX-like patients. AUC value reﬂecting the discrimination between groups is indicated.
F. Barzaghi et al. / Journal of Autoimmunity 38 (2012) 49e58 53allogeneic antigen presenting cells (APC), irradiated at a dose of
30 Gy and anti-CD3/CD28 mAb, and proliferation was evaluated by
3[H]-thymidine incorporation after 5 days of co-culture with Treg
cells, as elsewhere described [20].2.5. Statistical analysis
Results are presented as median and range. Differences between
groups were analysed with the non-parametric ManneWhitney U-
test and the relationship between numeric variables by means of
Pearson correlation index, as indicated in the text and ﬁgure
legends. To take into account possible outliers, we estimated
a robust regression linear model bymeans of high breakdownpoint
MM-type estimators.
For the quantitative evaluation of the FOXP3 methylation-
based discrimination of IPEX-like patients vs HS and patients
with other disease controls, the area under the “receiver oper-
ating characteristics” (ROC) curve (AUC) value and its associated
p-value were used. This is equivalent to the probability that
a randomly selected IPEX-like patient shows a lower percentage
of bona ﬁde Treg (TSDR-demethylated) cells in peripheral blood
than a randomly selected normal control or pathologic control.
No discriminative ability corresponds to an AUC of 0.5. A perfect
discrimination has an AUC of 1.0. All the analyses were performed
with SPSS and R environment. p-values lower than 0.05 were
considered signiﬁcant.3. Results
3.1. Clinical manifestations in IPEX-like patients
As described in Table 1, the onset of the disease ranged from 1
month (patient #1) to 19 years (patient #19), with only 4/23
patients showing a neonatal disease onset (patients #1, #14, #16
and #22). Themost frequent clinical feature in the present cohort of
IPEX-like patients was enteropathy, which occurred at variable age.
In 20/23 patients the enteropathy involved the small bowel with
histological ﬁndings including variable degree of villous atrophy
and/or a polymorphic inﬂammatory inﬁltrate, and usually pre-
senting as watery diarrhoea and weight loss, unresponsive to any
dietary restriction, including gluten free diet, elemental enteral diet
or total parenteral nutrition. An infectious origin of the enteropathy
was excluded in all but three patients (#1, #15 and #22). In two of
them early onset CMV infection was associated with CD25 deﬁ-
ciency, which did not allow persistent clearance of the virus.
Moreover, in three patients (#17, #21 and #23), there was evidence
of colonic inﬂammation, while in other two cases (#19 and #20) an
autoimmune atrophic gastritis was found. Remarkably, serological
screening for celiac disease and autoimmune enteropathy with
detection of anti-transglutaminase and anti-enterocyte auto-anti-
bodies, respectively, resulted negative.
Skin involvement was the second most common sign (16
patients outof 23), althoughwith awide spectrumof characteristics.
In most patients the eczematous lesions were similar to atopic or
F. Barzaghi et al. / Journal of Autoimmunity 38 (2012) 49e5854severe psoriasiform dermatitis and erythrodermia, vitiligo, nodular
eritema, bullous pemphigoid and urticaria-like lesions could be also
present. Notably, alopecia affected 4 patients (#1, #6, #18, #20).
T1DM was diagnosed in 7 out of 23 patients and in 6 of them it
was associated with enteropathy.
Additional disease features included: i) other autoimmune
disorders (in 7/23) such as thyroiditis, cytopenias, hepatitis, chol-
angitis, ankylosing spondylitis; ii) immunological disorders, such as
IgA deﬁciency (2/23), IgG deﬁciency (2/23), and slightly to mark-
edly increased levels of IgE (3/23) and eosinophils (1/23); iii)
recurrent and severe infections (10/23).
According to the severity of enteropathy and of autoimmune
manifestations, immunosuppressive therapy (IS) was administered
in 15/23 patients achieving partial control of the clinical picture.
Eight patients did not require any systemic IS, they received at
least hormone replacement, immunoglobulins, antibiotics and
supportive therapy.
Taken together, these ﬁndings indicate that patients affected
with IPEX-like syndrome can be identiﬁed on the basis of the same
clinical features used for the diagnosis of IPEX syndrome, including
enteropathy, T1DM and skin disease, although IPEX-like may
include female patients. The main difference lies in the greater
variability of these symptoms in IPEX-like patients, in terms of age
at onset and severity. Indeed, the onset can occur in infants or in
young adults, intestinal manifestations can involve also the
stomach and the colon, skin lesions occur not only as eczema but
also with a wide range of clinical and histological ﬁndings. In
addition, multiple autoimmune disorders appear especially with
increasing age. Finally, unlike IPEX syndrome, the IPEX-like disease
has a slower progression and it is better controlled by IS therapy.
Patients with CD25 deﬁciency represent an exception to this latter
observation, since their clinical manifestations may be as severe
and acute as in IPEX syndrome.Table 2
Parallel evaluation of Treg cell counts by TSDR demethylation analysis, FOXP3þ and
FOXP3þCD25þ T cells percentage by ﬂow cytometric analysis and MFI in IPEX-like
patients.
# Treg
(%)
FOXP3þ cells
(% in CD4þ gate)
FOXP3
MFI
CD25þFOXP3þ cells
(% in CD4þ gate)
CD25
MFI
5 0.89 8.36 568 5.21 na
9 0.89 18.19 413 17.05 1569
10 0.95 5.58 391 5.14 754
11 0 3.58 259 2.75 850
13 1.04 13.75 553 8.81 451
16 0.56 1.88 422 1.59 1334
17 0.83 2.70 440 1.92 2292
18 0.91 3.09 763 2.53 587
19 0.54 2.90 493 2.15 1879
20 0.67 2.26 390 2.01 848
21 0.94 9.70 1017 9.25 1185
22 0.67 2.45 550 1.45 759
23 0.74 0.35 476 0.35 610
na: not available.3.2. A quantitative defect of Treg cells is identiﬁed by TSDR
demethylation analysis in IPEX-like patients
The amount of Treg cells in the peripheral blood was deter-
mined by TSDR demethylation analysis and it is expressed as
percentage of nucleated cells. Results showed a median Treg cell
amount of 0.67% in IPEX-like patients (n ¼ 28; range from 0 to
2.83%) and of 1.40% in HS (n ¼ 40; range from 0.56 to 3.42%)
(Fig. 1A). These data indicate that, taken as a whole, IPEX-like
patients have a signiﬁcantly reduced percentage of peripheral
Treg cells, as compared to HS (p < 0.001). Importantly, analysis of
the ROC curve showed an AUC of 0.90 (p < 0.001). Considering
a cut-off value of 1.07% Treg cells (the value minimizing the
distance between the curve and the upper left corner of the graph),
the test has a sensitivity of 96% and a speciﬁcity of 80%, thus sup-
porting the observation that TSDR analysis discriminates IPEX-like
patients from HS (Fig. 1B).
Since the absolute number of lymphocytes physiologically
decreases with age [33], we further analysed the amount of Treg
cells across the different ages. Indeed, in pediatric HS (n ¼ 27; 16
years of age; Treg range 0.56%e3.42%; median 1.48%) a signiﬁcant
age-dependent decrease of Treg cells was observed (Pearson
correlation ¼ 0.556, p ¼ 0.003) (Fig. 1C). On the contrary, in
pediatric IPEX-like patients, we did not observe any decrease in
Treg cell amount in relation to age (n ¼ 22; 16 years of age; Treg
range 0%e2.83%; median 0.70%) (Fig. 1D). In adult IPEX-like
patients (n ¼ 6; >16 years of age) and HS, Treg cell amount did
not correlate with age (not shown), but the Treg percentage was
conﬁrmed to be consistently lower in patients (from 0.51% to 0.94%;
median 0.60%) than in HS (from 0.72% to 3.25%; median 1.34%).Thus, in paediatric and adult IPEX-like patients, Treg cells are
constantly reduced as compared to HS regardless of age.
3.3. Flow cytometric analysis may not detect a peripheral Treg cell
defect
In 13/28 IPEX-like patients TSDR demethylation could be eval-
uated in parallel to the ﬂow cytometric analysis for Treg cell
quantiﬁcation. Results showed that the percentages of FOXP3þ and
CD25þFOXP3þ T cells, in gated CD4þ T cells, ranged from 0.3 to 18%
(median ¼ 3%) and from 0.3 to 17% (median ¼ 2.5%), respectively
(Fig. 2A, B; Table 2). In HS (n ¼ 25), FOXP3þ T cells ranged from 2 to
8% (median ¼ 5.7%) and CD25þFOXP3þ T cells from 1.2 to 6.6%
(median ¼ 4.3%) (Fig. 2A, B). Thus, according to ﬂow cytometric
analysis, median values obtained in IPEX-like patients were not
signiﬁcantly lower than those detected in HS (p¼ 0.207 for FOXP3þ
Tcells and p¼ 0.185 for CD25þFOXP3þ Tcells). However, the former
group had a highly variable amount of FOXP3 expressing T cells,
whereas HS displayed a more narrow distribution of FOXP3þ T cells
(Fig. 2A, B). Addition of the negative Treg cell marker CD127 to the
analysis did not reveal any signiﬁcant difference in the size of the
FOXP3þ T cell population of IPEX-like patients as compared to HS
(data not shown). These results indicate that, despite the reduced
Treg cell amount detected by TSDR analysis, the frequency of FOXP3
expressing cells measured by FACS analysis is not decreased in the
peripheral blood of IPEX-like patients as compared to healthy
donors. Analysis on a per-cell base (mean ﬂuorescence intensity,
MFI) revealed a weaker FOXP3 expression (in the CD4þFOXP3þ T
cell gate) in patients as compared to HS (p ¼ 0.039), suggestive of
the presence of FOXP3þ activated Teff cells, rather than Treg cells, in
which FOXP3 expression is stably high [24]. CD25 MFI was not
signiﬁcantly different in patients and HS (p ¼ 0.057) (Fig. 2C, D).
Overall, these data highlight a discrepancy between results ob-
tained by the TSDR demethylation analysis and the ﬂow cytometric
data. This discrepancy is mainly evident in patients with high
frequency of FOXP3þ and CD25þFOXP3þ cells in the CD4þ Tcell gate
(Table 2). Thus, TSDR demethylation assay is more accurate than
the ﬂow cytometric analysis in the detection of peripheral Treg
cells, especially when there is an overall increase of activated Tcells.
3.4. Treg cell quantitative defect is conﬁrmed by analysis of Treg
cells within the CD3þ T cell compartment, as determined by TLSDR
analysis
In order to clarify whether the Treg cell number measured by
TSDR analysis could be inﬂuenced by the amount of CD3-
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CD3þ cells, as determined by TLSDR demethylation assay. As shown
by Pearson correlation analysis, both HS and IPEX-like patients
showed a direct correlation between the total T cell and Treg cell
percentage (Pearson correlation was 0.476 in patients, p ¼ 0.010,
and 0.617 in HS, p< 0.001). However, Treg cells in IPEX-like patients
did not maintain the same ratio to CD3-expressing T cells, as in HS
(Fig. 3A). Robust regression analysis revealed two different patterns
with slope 0.03 and 0.50 for patients and HS, respectively; p-value
for the difference of the slopes was <0.001 (1.27e-05).
In HS, CD3þ T cell distribution by TLSDR analysis ranged from
14.9% to 61.5% (median ¼ 29.5%), whereas two groups of IPEX-like
patients could be identiﬁed: one comprising lymphopenic patients
(n ¼ 11) with TLSDR < 14.9% (i.e. the minimum value detected in
HS), and a second group with TLSDR comparable to that of HS. The
percentage of Treg cells within the CD3þ T cell population resulted
highly variable in the group of lymphopenic patients (region (I),
Fig. 3B), whereas it was more homogeneous in non-lymphopenic
patients (n ¼ 17, region (II), Fig. 3B). Overall, in the latter group
a signiﬁcant reduction of Treg cells could be detected (Fig. 3C), as
compared to HS (Treg % in CD3þ T cells median and range were:
3.05 and 1.68e9.53 in IPEX-like; 4.89 and 1.87e10.78 in HS;
p < 0.001). We could not detect different distribution of patients
with or without IS therapy (not shown). The same analysis per-
formed in IPEX patients (n ¼ 5), who are not lymphopenic, showed
that Treg cells, although FOXP3-mutated, were present in higher
amount than those detected in IPEX-like patients (Treg % in CD3þ T
cells median and range: 9.84 and 6.79e20.79; p ¼ 0.007) (Fig. 3C).
As additional pathological controls we measured the percentage of
Treg cells in CD3þ T cells in patients affected with diseases whose
clinical features are also present in IPEX-like syndrome, but with
clear different diagnosis, i.e. patients with T1DM (median and
range: 4.53% and 3.43e6.90%, respectively), celiac disease (median
and range: 4.32% and 3.12e6.44%, respectively) and Crohn’s disease
(median and range: 5.13% and 3.96e9.38%, respectively). In all three
groups the frequency of Treg cells was not different from that
detected in HS (T1DM: p ¼ 0.522; celiac disease: p¼ 0.269; Crohn’s
disease: p ¼ 0.492) and it was signiﬁcantly higher as compared to
IPEX-like patients (T1DM: p ¼ 0.005;celiac disease: p ¼ 0.026;
Crohn’s disease: p ¼ 0.001).
Notably, statistical evaluation of the results obtained from HS
and IPEX-like patients through the ROC curve, showed 80% prob-
ability to distinguish between IPEX-like patients and HS
(AUC ¼ 0.80, p<0.001) based on the percentage of Treg/CD3
determined by TSDR and TLSDR analysis. Considering a cut-off
value of 3.75% Treg cells in the T cell compartment, we obtained
a sensitivity of 87%, a speciﬁcity of 65% (11 out of 17 patients
showed a percentage of Treg cells below the cut-off), and an
accuracy of 78% (Fig. 3D). Similarly, the TSDR/TLSDR assay showed
82% probability to distinguish IPEX-like patients from patients with
different pathologies with overlapping symptoms (AUC ¼ 0.82;
Supplementary Fig. 1). Thus, also the combined demethylation
analysis of TSDR and TLSDR is a valid method allowing discrimi-
nation of IPEX-like patients from HS, patients with FOXP3 muta-
tions and patients with different autoimmune and
autoinﬂammatory diseases.
3.5. Treg cells from IPEX-like patients display preserved suppressive
function
In order to investigate whether Treg cells from IPEX-like
patients retained suppressive function, CD4þCD25þ Treg cells
were puriﬁed from the peripheral blood of four patients (patients
#15, 16, 17 and 20) and tested in vitro to evaluate their capacity to
inhibit the proliferation of allogeneic and/or autologous respondercells (Fig. 4). Treg cells from all patients tested displayed preserved
suppressive activity. With the exception of patient #16, suppressive
activity was comparable to that of control Treg cells tested in
parallel versus both CD4þ and CD8þ T cells from HS, used as
responder cells (n ¼ 3) (p > 0.05, Wilcoxon signed rank test).
Inhibitory capacity was also maintained when patients’ PBMCwere
used as responder cells (n ¼ 3, for patients’ CD4þ responder cells
and n¼ 2 for patients CD8þ responder cells) (Fig. 4A and B). Further
functional characterization of patients’ Treg cells revealed that,
similar to those of HS, CD4þCD25þ T cells from patients were
hypoproliferative (not shown). These results indicate that Treg cell
suppressive function in patients with IPEX-like syndrome is fully
preserved.
4. Discussion
IPEX-like syndrome is a heterogeneous nosological entity that
remains mostly of unknown origin, although speciﬁc primary
immunodeﬁciencies can be distinguished therein, such as genetic
defects in CD25 [7,15]. In the present study, we examined a cohort of
28 patients with clinical features resembling IPEX syndrome in the
absence of FOXP3 mutations. We show that the large majority of
these IPEX-like patients have low frequency of peripheral Treg cells,
detected with high sensitivity and speciﬁcity by TSDR demethyla-
tion assay. Thus, we provide evidence that a quantitative defect of
Treg cells can be considered a biological hallmark of IPEX-like
syndrome.
For the ﬁrst time, we describe a large cohort of patients pre-
senting with IPEX-like syndrome, in which, similarly to IPEX,
autoimmune enteropathy is the most frequent clinical feature
together with skin lesions and other autoimmune manifestations,
such as T1DM. However, unlike in IPEX, in IPEX-like syndrome the
enteropathy has a variable age of onset and also females can be
affected. Skin involvement is mostly characterized by eczematous
lesions, although a wide spectrum of skin pathologies can be
observed. Other autoimmune symptoms comprise thyroiditis,
cytopenias, hepatitis, cholangitis, atrophic gastritis, and ankylosing
spondylitis. Immunological disorders such as IgA deﬁciency, hy-
pogammaglobulinemia, and increased serum IgE levels can be
present, together with high eosinophil counts. Despite several
clinical similarities with IPEX syndrome, which justify the general
deﬁnition as IPEX-like, the course of the disease is less severe and
patients show better therapy response.
In the attempt to investigate the pathogenesis of the disease, we
and others have questioned whether the Treg compartment is
affected as in IPEX syndrome. Previous studies, using ﬂow cyto-
metric analysis led to insufﬁcient results to support the hypothesis
of a Treg cell reduction [8,9]. These data include an evaluation of
Treg cells, previously performed in ﬁve IPEX-like patients (all under
IS therapy), among whom, three were diagnosed with low
CD25þCD127dimFOXP3þ T cell counts, and two others had a normal
proportion of these cells [8, 9].
In the present cohort of IPEX-like patients, using the highly
Treg-speciﬁc TSDR demethylation assay [34], we were able to
identify a consistent quantitative deﬁciency of Treg cells. The defect
could not be detected by ﬂow cytometry that showed, on the
contrary, variable results. The discrepancy between demethylation
and ﬂow cytometric analysis was particularly evident in patients
with the highest number of CD4þFOXP3þ T cells (patient #9 and
#21, who had a low amount of TSDR-demethylated cells). These
data suggest that, in the presence of activated Teff cells, transiently
expressing CD25 and FOXP3 [24,35], ﬂow cytometric analysis loses
speciﬁcity to quantify peripheral bona ﬁde Treg cells. This limitation
is more likely to occur in patients with ongoing autoimmunity and,
therefore, high amount of circulating activated T cells. Thus,
Fig. 4. Suppressive function of Treg cells isolated from the peripheral blood of IPEX-like patients. CD4þCD25þ T cells isolated from the peripheral blood of IPEX-like patients were
used as suppressor cells in a suppression assay, using allogeneic and/or autologous PBMC as responders. CD4þCD25þ T cells isolated from the peripheral blood of one HS were tested
in parallel and used as control. (A) Histograms of CFSE dilution of one representative patient (#20) are shown. Analysis was performed by gating either on CD4þ or on CD8þ
responder T cells. Numbers in the plots indicate percent inhibition. The relative [suppressor: PBMC responder] cell ratio is also indicated. (B) Average %inhibition of proliferation
versus the indicated responder cells is plotted in the graphs. The highest [suppressor: responder] cell ratio tested is plotted for each patient. Black symbols refer to patients, white
symbols to HS tested in parallel. C: Patient #20; :: Patient #17; -: Patient #15; A: Patient #16.
F. Barzaghi et al. / Journal of Autoimmunity 38 (2012) 49e5856especially in these conditions, TSDR demethylation analysis
emerges as a key complementary method to evaluate bona ﬁde Treg
cell amount. Moreover, the combined analysis of TSDR and TLSDR
demethylation allows quantiﬁcation of Treg cells within the total
amount of T cells, so that Treg cells can be studied in lymphopenic
and non-lymphopenic patients. Indeed, in non-lymphopenic IPEX-
like patients, the low number of Treg cells was conﬁrmed, sug-
gesting that autoimmunity could be sustained by an unbalanced
Treg/T cell ratio, with consequent insufﬁcient amount of Treg cells
to control pathogenic Teff cells. Furthermore, our results demon-
strate that the Treg cell reduction is a feature speciﬁc for patients
with IPEX-like syndrome, since it is not detected in patients with
other autoimmune pathologies of different origin. On the contrary,
a different aetiology of the autoimmunity can be hypothesized in
lymphopenic patients, in whom the reduction of Treg cells is
associated with an overall decreased amount of CD3þ T cells.
Statistical evaluation of results through the ROC curve showed
that both methods have high probability to discriminate between
IPEX-like patients and HS: 90% (AUC ¼ 0.90) considering the TSDR
demethylation analysis alone, and 80% (AUC ¼ 0.80) using the
combined TSDR/TLSDR demethylation analysis. The latter assays
also allow the distinction between IPEX-like patients and other
pathologic controls (AUC ¼ 0.82). Hence, parallel demethylation
analysis of TSDR and TLSDR identiﬁes a biological parameter,
alternative or complementary to ﬂow cytometry, which permits
precise Treg cell quantiﬁcation and exclusion of concomitant lym-
phopenia, often characterizing primary immunodeﬁciencies. In
addition, demethylation analysis can be performed with lowamount of biological material (i.e. less than 200 mL of peripheral
blood), allowing highly reproducible quantiﬁcation of Treg cells
even in infants, in whom blood sampling is limited.
Despite reduced in number, Treg cells of IPEX-like patients
displayed preserved suppressive function in all patients tested.
Previous studies reported that Treg cell in vitro function in patients
with autoimmune enteropathy, without FOXP3 mutations could
vary fromnormal to reduced in relationship with the level of FOXP3
expression [8,9]. Interestingly, all the patients that we tested had
low frequency of Treg cells as measured by TSDR assay. When the
percentage of Treg cells was normalized by TLSDR, only in two out
of four patients (patients #15 and 20), both with fully preserved
in vitro suppressive activity, the Treg cell frequency was below the
cut-off value, thus suggesting that in these patients autoimmunity
may indeed be due to reduced Treg cell frequency. In one patient
(patient #16) the overall low Treg cell number was due to presence
of lymphopenia, as demonstrated by TLSDR assay. In this case the
quantitative assay is not informative, since Treg cells were not
speciﬁcally undersized with regard to the Teff cell compartment. In
addition, their function resulted partially defective, thus leaving the
possibility that in this patient the pathology could be due to
a complex defect including the functional impairment of Treg cells
alone or rather of multiple T cell subsets. In the last patient tested
(patient #17) both Treg cell number and function were comparable
to healthy subjects, thus indicating that the defect underlying the
disease is likely to affect the effector rather than the regulatory T
cell compartment, as also indicated by the partial resistance to
suppression of patient’s responder cells. Overall, our functional
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patients, although clearly identiﬁes a cohort in which the quanti-
tative Treg defect is present. Our approach allows the rapid and
precise identiﬁcation of this subgroup of patients, who would
potentially beneﬁt from innovative therapies based on the adoptive
transfer of ex-vivo expanded autologous Treg cells.
The reduction of Treg cells has been observed in other autoim-
mune diseases [36,37], but the causes of this reduction still need to
be clariﬁed. The unbalance between the Treg/Teff compartments
may be due either to defective homeostatic proliferation of the
peripheral Treg cell pool as compared to the conventional T cell
pool, or to impairment of peripheral Treg cell survival. Alterna-
tively, Treg cells may be reduced due to impaired thymic devel-
opment and/or migration to periphery. Further studies on patients
affected with IPEX-like syndrome are required to identify the bio-
logical/molecular cause of the Treg cell decrease.
Overall, we propose TSDR and TLSDR demethylation analysis as
reliable tools for the quantitative evaluation of Treg cells in patients
with immune dysregulation, allowing the identiﬁcation of a defect
otherwise not detectable in IPEX-like patients, integrating ﬂow
cytometric evaluation, especially in the presence of inﬂammation,
and standardizing the quantiﬁcation of Treg cells. Our analysis
provides new insights into the pathogenesis of at least a subset of
IPEX-like patients, in whom autoimmunity can be ascribed to the
unbalance between the Treg/Teff compartments, thus paving the
way for the development of targeted therapies.
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